Treatment of Uterine Myoma with 2.5 or 5 mg Mifepristone Daily during 3 Months with 9 Months Posttreatment Followup: Randomized Clinical Trial

Table 5

Changes in endometrial thickness (mm) by treatment groups and evaluation periods.

Evaluation at	Group	𝑛	Mean ± S.D.	95% CI for mean	Changes (%)	𝑃^∗
Before treatment	2.5 mg	110	6.8 ± 1.9	6.5–7.3	—	1.000
	5 mg	110	6.8 ± 1.9	6.4–7.3
3-month treatment	2.5 mg	102	8.9 ± 3.7	7.9–9.4	30.9 ↑	.846
	5 mg	106	9.0 ± 3.7	8.4–10.0	32.3 ↑
3-month followup	2.5 mg	98	7.7 ± 2.3	7.1–8.2	13.2 ↑	.758
	5 mg	104	7.8 ± 2.3	7.3–8.3	14.7 ↑
6-month followup	2.5 mg	93	7.7 ± 2.4	7.2–8.3	13.2 ↑	.594
	5 mg	103	7.9 ± 2.8	7.3–8.3	16.2 ↑
9-month followup	2.5 mg	90	7.5 ± 1.9	7.1–7.9	10.3 ↑	1.000
	5 mg	100	7.5 ± 2.5	7.0–8.0	10.3 ↑

^∗𝑡-test (ANOVA); CI: confidence interval, SD: standard deviation.